Universal Miracle Drug Exosomes: Three Unregistered Products, Multiple Exposed Companies Previously Subject to Administrative Penalties

(Source: Caixin)

The CCTV 315 Gala exposed companies related to the so-called “万能” (万能) exosomes, with details of the involved companies listed in the full article.

On the evening of March 15, CCTV’s 315 Gala revealed the scam involving exosomes, which are not approved by the government, have not undergone any clinical trials, and lack any efficacy data. These so-called “exosomes” are packaged by some companies as “panacea” cures, even injected into patients’ bodies through “proxy injections,” and the business profits are quite substantial.

The companies related to the “万能” exosomes exposed by CCTV’s 315 Gala are as follows:

Tianjin Chengxing Medical Beauty Clinic Co., Ltd.

Trademark application rejected

Tianyancha app shows that Tianjin Chengxing Medical Beauty Clinic Co., Ltd. was established in February 2018. The legal representative is Ding Yu, with a registered capital of 1 million RMB. Its business scope includes cosmetic and medical beauty services, jointly held by Tianjin Haojing Technology Co., Ltd. and Ding Yu. According to annual report data, the company has 3 insured employees in 2024. Intellectual property information indicates that the two graphic trademarks applied for by the company have been rejected and invalidated.

Tianjin Hedong Meilai Medical Beauty Hospital Co., Ltd.

Repeated fines and lawsuits over medical disputes

Tianyancha app shows that Tianjin Hedong Meilai Medical Beauty Hospital Co., Ltd. was established in March 2014. The legal representative is Qiu Changgui, with a registered capital of 30 million RMB. Its scope includes medical beauty services, medical services, and daily beauty services, jointly held by Meilai Medical Beauty Group Co., Ltd. and Xiamen Huayi Medical Investment Co., Ltd.

Risk information indicates multiple administrative penalties, including a fine in July 2025 for illegal advertising, a penalty in June 2024 for improper use of medical devices outside their scope, and a warning in April 2021 for storing anesthetics and Class I psychotropic drugs improperly. The company has also been sued multiple times over medical disputes.

Zhengzhou Yuanchuang Gene Technology Co., Ltd.

Multiple patents rejected

Tianyancha app shows that Zhengzhou Yuanchuang Gene Technology Co., Ltd. was established in February 2016. The legal representative is Zhao Yan, with a registered capital of 22.2 million RMB. Its business scope includes stem cell and immune cell collection, storage, preparation, and technical research, as well as clinical research and translational applications of stem cells and immune cells, jointly held by Zhao Hui, Rui Ji (Shenzhen) Investment Consulting Partnership (Limited Partnership), and Hainan Furuivo Investment Co., Ltd. Zhao Hui holds 60.3604% of shares and is the actual controller, also serving as a director of A-share company Berriy Gene (000710.SZ).

Intellectual property data shows that several patents have been rejected, including methods for cryopreservation of immune cells and preparation of skin fibroblasts.

Hunan Lise Pharmaceutical Co., Ltd.

Fined and confiscated 220,000 RMB last year

Tianyancha app shows that Hunan Lise Pharmaceutical Co., Ltd. was established in June 2021. The legal representative is Xiao Jingyang, with a registered capital of 3 million RMB. Its scope includes medical device technology development and health industry project management, among others, held by Xiao Shuang and Xiao Jingyang. Administrative penalties indicate that in June 2025, the company was fined over 220,000 RMB for violations of the “Medical Device Supervision and Administration Regulations.”

Haolin (Tianjin) Biotechnology Co., Ltd.

Previously awarded a community health service center procurement project

Single project amount: 645,000 RMB

Tianyancha app shows that Haolin (Tianjin) Biotechnology Co., Ltd. was established in June 2019. The legal representative is Zhang Cheng, with a registered capital of 10 million RMB. Its scope includes human stem cell technology development and application, genetic diagnosis and treatment technology development, cell technology R&D and application, among others, jointly held by Wan Zhiheng and Zhang Cheng.

Bidding information shows that last September, the company won the bid for the procurement project of the Fumin Road Community Health Service Center in Hedong District, Tianjin.

External investments include three companies: Haolin Biopharmaceuticals (Tianjin) Co., Ltd., Haolin (Beijing) Medical Technology Co., Ltd., and Tianjin Que Ming Biomedical Engineering Research Co., Ltd. The company has applied for multiple patents, including “a device for lyophilizing human collagen” and “an MRI data optimization method for sarcopenia diagnosis and assessment.”

Sichuan Jiebosaier Biotechnology Co., Ltd.

Zero insured employees in 2024

Tianyancha app shows that Sichuan Jiebosaier Biotechnology Co., Ltd. was established in May 2024. The legal representative is Tan Yang, with a registered capital of 10 million RMB. Its scope includes cell technology R&D and application, human stem cell technology development and application, and health consulting services, jointly held by Sichuan Jiebosaier Health Management Co., Ltd. and Tan Yang. The insured employee count for 2024 is zero.

Intellectual property data shows that last year, the company applied to register multiple “Yijue Wan” trademarks in categories including advertising sales, beer beverages, and convenience foods. The trademarks are currently awaiting substantive examination.

Sichuan Huamei Zixun Plastic Surgery Hospital Co., Ltd.

Repeated fines

Tianyancha app shows that Sichuan Huamei Zixun Plastic Surgery Hospital Co., Ltd. was established in June 2008. The legal representative is Lin Guoqiang, with a registered capital of 10 million RMB. Its scope includes medical services, medical beauty services, daily beauty services, and second-class value-added telecommunications services, jointly held by Meilai Medical Beauty Group Co., Ltd. and Xiamen Huayi Medical.

Risk information indicates that in October 2025, the company was fined by Chengdu High-tech Zone Market Supervision Administration for violating advertising content. In October 2024, it was fined 30,000 RMB by the Sichuan Provincial Market Supervision Administration for violating the Advertising Law.